Abbott Laboratories stock slides 1.46% and underperforms competitors
Updated
Updated · MarketWatch · May 1
Abbott Laboratories stock slides 1.46% and underperforms competitors
15 articles · Updated · MarketWatch · May 1
Shares closed at $89.46 on Friday, marking a third straight daily loss, as the S&P 500 rose 0.29% and the Dow Jones Industrial Average fell 0.31%.
Abbott lagged Johnson & Johnson, down 1.16%, and Pfizer, down 1.39%, while Merck outperformed with a 2.73% gain.
The stock finished 35.67% below its 52-week high of $139.06 reached on 24 June, while trading volume of 12.8 million topped its 50-day average of 11.9 million.
Could Abbott's ongoing product safety issues and lowered guidance undermine its reputation as a dividend aristocrat and long-term growth leader?
How might Abbott's regulatory hurdles and Exact Sciences integration reshape its future in the fast-evolving, AI-driven healthcare landscape?